Comparative Pharmacology
Head-to-head clinical analysis: CENTRAX versus CLOBAZAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENTRAX versus CLOBAZAM.
CENTRAX vs CLOBAZAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptors, enhancing chloride ion influx and hyperpolarization of neurons, resulting in anxiolytic, sedative, and muscle relaxant effects.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
10-30 mg orally, 3-4 times daily.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
None Documented
None Documented
60-120 hours (mean 100 hours); long half-life leads to accumulation upon multiple dosing and prolonged sedation.
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Renal (primarily as glucuronide conjugates; <1% unchanged); biliary/fecal: minimal (less than 5%).
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Erythromycin can be decreased when combined with Clobazam."